Joe Biden diagnosed with aggressive prostate cancer

Published 19/05/2025, 01:06
© Reuters

Investing.com-- Former U.S. President Joe Biden, 82, has been diagnosed with an aggressive form of prostate cancer that has metastasized to his bones, according to a statement released by his office on Sunday.

The diagnosis followed a medical evaluation prompted by urinary symptoms, revealing a prostate nodule. Tests confirmed a Gleason score of 9, indicating a high-grade, fast-growing cancer.

Despite the severity, Biden’s medical team noted the cancer is hormone-sensitive, allowing for potentially effective treatment options. He and his family were currently consulting with physicians to determine the best course of action.

President Donald Trump extended wishes for a "fast and successful recovery," while Vice President Kamala Harris expressed confidence in Biden’s resilience.

Biden, who concluded his presidency in January 2025, has been a prominent advocate in the fight against cancer, notably through initiatives like the Cancer Moonshot.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.